Form 4: Arrowhead CMO Sells 15,000 Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 15,000 shares of common stock for $30 per share on September 12, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), reported a sale of company common stock.
• The transaction involved the disposition of 15,000 shares of common stock.
• The shares were sold at a price of $30 per share.
• The sale occurred on September 12, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following the sale, Mr. Hamilton beneficially owns 232,122 shares of common stock, which includes previously reported shares underlying Restricted Stock Units subject to certain vesting conditions.

Sentiment

Score: 4

Explanation: The filing reports an insider sale of common stock by the Chief Medical Officer. While executed under a pre-arranged 10b5-1 trading plan, which suggests the sale was not based on new material non-public information, insider selling can still be interpreted by the market as a reduction in management's direct stake and confidence.

Positives

• The transaction was made pursuant to a Rule 10b5-1 trading plan, indicating the sale was pre-scheduled and not based on new material non-public information, which provides transparency and reduces concerns about market timing.

Negatives

• Chief Medical Officer James C. Hamilton reduced his direct ownership in the company by selling 15,000 shares, which can sometimes be perceived by the market as a reduction in management's direct stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal regarding management's direct equity exposure, although the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The reported insider sale by the Chief Medical Officer, while significant in volume, was conducted under a pre-arranged 10b5-1 trading plan. This indicates the transaction was scheduled in advance and not based on new material non-public information, thus reducing its immediate signaling impact. A single Form 4 filing, particularly one under a 10b5-1 plan, typically does not warrant a change in fundamental investment recommendation without additional context or a pattern of insider activity.

Keywords

ARWR, Arrowhead Pharmaceuticals, James C. Hamilton, insider trading, Form 4, stock sale, 10b5-1 plan, Chief Medical Officer